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Abstract
Introduction: Due to high rates of response and durable remissions, imatinib (Glivec®, or Gleevec®
in the USA; Novartis Pharma AG) is the standard of care in patients with chronic myeloid leukemia.
Recently, a non-authorized product which claims comparability to imatinib has become available.
Case presentation: This report describes the loss of response in a 36-year-old male patient with
chronic-phase chronic myeloid leukemia who had previously been in full hematologic and cytogenetic
remission and partial molecular remission for three years, under treatment with brand-name imatinib
of 400 mg per day. Before the initiation of treatment with a copy product, imatib (CIPLA-India), the
patient had negative BCR-ABL status. Within three months of initiation of treatment with the copy
product, the patient’s BCR-ABL status became positive, with substantial decreases noted in white
blood cell counts, red blood cell counts and platelet counts. Conversion of the BCR-ABL status to
negative and improvements in hematologic parameters were achieved when the brand medication,
imatinib, was resumed at a dose of 600 mg per day.
Conclusion: In our patient, the substitution of a copy product for imatinib resulted in the rapid loss
of a previously stable response, with the risk of progression to life-threatening accelerated phase or
blast crisis phase of the disease. Without supportive clinical evidence of efficacy and safety of imatib
(or any other copy product) caution should be used when substituting imatinib in the treatment of
any patient with chronic myeloid leukemia.
Introduction
Imatinib, a potent and selective inhibitor of the protein
tyrosine kinase BCR-ABL, has shown significant clinical
activity in chronic myeloid leukemia (CML), producing
durable responses and prolonged survival [1,2]. As such,
imatinib (Glivec®, or Gleevec® in the US; Novartis Pharma
AG) is considered the first-line standard of care for the
treatment of patients with CML. Response to imatinib is
assessed by hematologic white blood cell count (WBC)
and platelet count; presence of extramedullary disease or
leukemic cells in the peripheral blood, cytogenetic,
percentage of Philadelphia chromosome-positive cells in
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the bone marrow, and molecular ratio of BCR-ABL to BCR
transcripts in the peripheral blood as measured by real-
time polymerase chain reaction [RT-PCR] parameters [1].
Long-term outcomes include freedom from progression to
advanced phases of the disease and survival.
In health-care systems where patients have to pay for
their own medicine, the cost of the medication can be an
obstacle to adequate compliance. In life-threatening
diseases, such as CML, a lapse in therapy may result in
suboptimal responses, progression to accelerated or blast
crisis phases of disease and mortality. Therefore, main-
tenance of response is of utmost importance.
A copy preparation, consisting of the alpha crystal form of
imatinib, has become commercially available under the
name ‘imatib’ (CIPLA-India) at a markedly reduced price.
The lower price has prompted some health-care autho-
rities and insurance payers to substitute the copy for
imatinib. The manufacturer of imatib lists the product as
being ‘comparable’ to imatinib [3], but the US regulatory
authority the Food and Drug Administration (FDA)
Orange Book does not have a listing of any products
with equivalence to imatinib.
Case presentation
A self-sponsored (that is, uninsured) 36-year-old man
diagnosed with chronic-phase (CP) CML (Sokal score 1.22
[low risk <0.8, high risk >1.2] and Hasford score 1158.6
[low risk <780, moderate 780 to 1480, high risk >1480])
had received imatinib 400 mg per day since the beginning
of January 2004. After approximately 10 months of
therapy, full hematologic and cytogenetic remission,
then major molecular remission had been achieved with
a %BCR-ABL/ABL International Scale (IS) score of about
0.01 compared to an initial value of 9. This status had been
maintained for approximately three years. In January
2007, his BCR-ABL scored negative by nested RT-PCR.
Subsequently, the patient sought medical insurance and
was switched by the insurer to the copy product imatib, at
the same dose of 400 mg per day. In March 2007, after
approximately three months of therapy with the ‘copy’
imatib, and despite a claimed compliance to the pre-
scribed regimen, substantial hematologic changes were
noted in the form of anemia (hemoglobin 9 g/dL),
neutropenia (WBC 2300/mm3 with an absolute neutro-
phil count (ANC) of below 1000), thrombocytopenia
(platelets 101,000/mm3) and loss of cytogenetic and
molecular responses. Cytogenetic and molecular assess-
ments demonstrated a ‘positive’ Philadelphia chromo-
some (22% Ph+ cells) and a %BCR-ABL/ABL ratio of 3,
consistent with a disease relapse and a probable hemato-
logical toxicity to the agent. The spleen was still impalp-
able and the Sokal score was 1.16. Tests for tyrosine kinase
mutations were not performed.
In May 2007, the patient resumed imatinib at a daily dose
of 600 mg per day. In July 2007, after approximately two
months of therapy with imatinib, laboratory values
revealed a return to a full hematologic and cytogenetic
response and in November 2007, after six months of
therapy, the patient achieved a %BCR-ABL/ABL score of
0.01. Changes in hematologic laboratory parameters at
baseline, following the change to the copy product with a
loss of response and subsequent return to treatment with
imatinib and reinstatement of response, are summarized
in Table 1.
Discussion
In the International Randomized Trial of Interferon versus
STI571 (IRIS), responses to first-line imatinib have been
remarkably durable [2]. Estimated annual rates of treat-
ment failure after the start of imatinib therapy were 3.3%
in the first year, 7.5% in the second year and 4.8% in the
third year. It is possible that the rapid loss of response that
followed the initiation of the copy product could have
been coincidentally due to treatment failure associated
with imatinib. However, the chronologic sequence of
events points to a direct relationship between the
initiation of the copy product and the loss of response
followed by improvement in hematologic status and
return to a negative BCR-ABL status that occurred after
imatinib was restarted. Improvement in cytogenetic
response following dose escalation of imatinib has been
documented in patients with poor initial response or
Table 1. Hematologic parameters at baseline, following change to imatib and return to imatinib therapy






Red blood cell count (n/mm3) 4,850,000 3,200,000 4,200,000
Hemoglobin (g/dL) 13.4 9 12.7
Total leukocyte count (n/mm3) 4200 2300 3800
Neutrophils 68% 34% 66%
Eosinophils 1% 7% 2%
Basophils 1% 8% 2%
Lymphocytes 24% 41% 25%
Monocytes 6% 10% 5%
Platelet count (n/mm3) 234,000 101,000 156,000
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treatment failure [4–7]. In our patient, due to the rapid
loss of response, the copy product was discontinued and
imatinib was reinstated at an escalated dose. Without
clinical trial data or documented clinical experience, it was
not possible to know whether the rapid loss of response
may have been attenuated or reversed by increasing the
dose of the copy product.
Copy products, such as that described in our patient,
should not be confused with generic equivalents to
branded pharmaceutical products. In the US, a generic
drug product is one that is comparable to an innovator
drug product in dosage form, strength, route of adminis-
tration, quality, performance characteristics (bioequiva-
lence) and intended use [8]. Copy products often differ
slightly in chemical structure and do not undergo clinical-
trial evaluation or regulatory review before their release to
market. Many of these products are offered for sale
without prescription through internet-based distributors.
Conclusion
While the copy product used by our patient is purported to
be comparable to imatinib, there is no published clinical
evidence that we are aware of to support this claim. In our
patient, substitution of the copy product for imatinib
resulted in rapid loss of a previously stable response. Loss of
response inCML can result in progression to life-threatening
accelerated phase or blast crisis phase of the disease.
The advent of therapies targeting tyrosine kinase resulted
in a breakthrough in the management of CML. For cost
reasons, some third-party insurers opt to use copy forms of
the drug that might not be as efficacious as the original
molecule. Every effort should be made to maintain
patients in remission on their proper medicine, and
careful follow-up is needed if patients who have achieved
remissions are shifted to copy medicines, to ensure that
the response is not compromised. Without supportive
clinical evidence of efficacy and safety of this (or any
other) copy product caution should be used in substitu-
tion of imatinib in any patient with CML.
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